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Oxidative stress appears to be an early event involved in the pathogenesis of Alzheimer’s disease. The present study was designed to
investigate the neuroprotective eﬀects of Centella asiatica against colchicine-induced memory impairment and oxidative damage
in rats. Colchicine (15μg/5μL) was administered intracerebroventricularly in the lateral ventricle of male wistar rats. Morris
water maze and plus-maze performance tests were used to assess memory performance tasks. Various biochemical parameters
such as lipid peroxidation, nitrite, reduced glutathione, glutathione-S-transferase, superoxide dismutase, acetylcholinesterase were
also assessed. ICV colchicine resulted marked memory impairment and oxidative damage. Chronic treatment with Centella
asiatica extract (150 and 300mg/kg, p.o.) for a period of 25 days, beginning 4 days prior to colchicine administration,
signiﬁcantly attenuated colchicine-induced memory impairment and oxidative damage. Besides, Centella asiatica signiﬁcantly
reversedcolchicinesadministeredincreaseinacetylcholinesteraseactivity.Thus,presentstudyindicatesprotectiveeﬀectofCentella
asiatica against colchicine-induced cognitive impairment and associated oxidative damage.
Copyright © 2009 Anil Kumar et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder and causes signiﬁcant dementia in elderly.
The neuropathological hallmarks of AD include deposits
of amyloid β ﬁbrils in senile plaques and presence of
abnormaltauproteinﬁlamentsintheformofneuroﬁbrillary
tangles [1]. Hippocampus, limbic system, and cortex are
the primary areas involved in the pathophysiology of AD
[2]. The etiopathogenesis of this disorder is multifactorial
and oxidative stress has been reported to play a signiﬁcant
role in the onset and progression of AD. Considering the
mechanistic aspects, it has been recognized that β-amyloid
aggregates and iron accumulation both synergistically cause
oxidative damage by free radical generation [3, 4]. Centrally
administered colchicine-induced cognitive dysfunction is a
well-known model that represents sporadic dementia of
Alzheimer’s type (SDAT) [5]. Colchicine, a microtubule
disrupting agent causes cytoskeletal alterations and axonal
transport dysfunction [6] leading to death of cerebellar
granule cells, olfactory bulb neurons, cells of subventricular
zone, dentate gyrus cells, and basal forebrain cholinergic
neurons [7], thus causing cognitive impairment. It induces
neuroﬁbrillary degeneration by binding to tubulin, principal
structural protein of microtubules [8], thereby inhibiting
axoplasmic transport, and mitosis [9]. In addition, central
administration of colchicine causes excessive free radical
generation and oxidative damage that can be positively
correlated with the extent of cognitive impairment [10].
Phytopharmaceuticalsaregainingimportanceasmodern
medicine as well as traditional system of medicine owing to
their therapeutic potential. Novel antioxidants may oﬀer an
eﬀective and safe means of bolstering body’s defense against
free radicals [11] and thereby provide protection against AD
like problems. Various natural antioxidants like curcumin,
rosmarinic acid, huperzine A have been reported to have
an e u r o p r o t e c t i v ee ﬀect against AD [12–14]. Centella asiat-
ica (CA) L. Urban (syn. Hydrocotyle asiatica L.) belonging to2 International Journal of Alzheimer’s Disease
Table 1
Group number Treatment
(1) Sham-operated (vehicle for CA)
(2) ACSF (5μL, ICV ) + vehicle for CA
(3) Colchicine (15μg/5μL) + vehicle for CA
(4) CA (150mg/kg, PO) + ACSF
(5) CA (300 mg/kg, PO) + ACSF
(6) CA (150mg/kg, PO) + colchicine
(7) CA (300mg/kg, PO) + colchicine
family Apiaceae (Umbelliferae) is a psychoactive medicinal
plant being used from centuries in Ayurvedic system of
medicine as a medhya rasayna [15]. It has been reported
to possess various pharmacological eﬀects on CNS such as
stimulatory-nervine tonic, rejuvenant, sedative, anxiolytic,
and intelligence promoting property [16]. Previous report
also demonstrated that Centella asiatica leaf extract involved
in the morphology of hippocampal CA3 and amygdal
neuronal dendritic arborization in neonatal rats. [17, 18].
The whole plant has been shown to improve general mental
ability of mentally retarded children [19]. It has also been
shown to decrease the oxidative stress parameters [16, 20].
However, its exact mechanism of action in the treatment
and management of Alzheimer disease has not been fully
understood.
Therefore, present study was designed to investigate the
possible neuroprotective eﬀect of Centella asiatica against
colchicine-induced cognitive impairment and associated
oxidative damage in rats.
2.MaterialsandMethods
2.1. Animals. Young male Wistar rats (180–200g) procured
from central animal house, Panjab University, Chandigarh
were used. Animals were acclimatized to laboratory condi-
tions at room temperature prior to experimentation. Follow-
ing surgery, animals were kept under standard conditions of
a 12-hour light/dark cycle with food and water ad libitum
in groups of 2, in plastic cages with soft bedding. All
the experiments were carried out between 9.00 AM and
3.00PM. The protocol was approved by the Institutional
Animal Ethics Committee of Panjab University, Chandigarh,
India, and carried out in accordance with the Indian
National Science Academy Guidelines for the use and care
of laboratory animals.
2.1.1. Surgery and Intracerebroventricular Administration of
Colchicines. Surgery was performed as per the previously
described protocol [10]. Animal was anesthetized with
thiopentalsodium(45mg/kg)andpositionedinastereotaxic
apparatus. The head was positioned in a frame and a
midline sagittal incision made in the scalp. Two holes were
drilled in the skull for the placement of the injection
cannulaintoboththelateralcerebralventricles.Co-ordinates
for the intracerebroventricular (ICV) cannula implantation
were 0.8mm posterior to bregma, 1.8mm lateral to the
sagittal suture, and 3.6mm beneath the cortical surface. The
scalp was then closed with a suture. Gentamicin (5mg/kg,
IP) was applied to the surgical area in order to prevent
sepsis. Animals were housed in a group of two with soft
bedding. Special care of the animals was taken during the
postoperative period to provide food and water inside the
cage of rats. Rats were infused ICV with either artiﬁcial
cerebrospinal ﬂuid (ACSF; in mmol/l: 147 NaCl, 2.9 KCl,
1.6 MgCl2,1.7 CaCl2, and 2.2 dextrose) or 15μg colchicine
dissolved in ACSF. Solution (5μL) was injected using a
Hamilton microsyringe positioned in the injection cannula
and the syringe was kept in place for 2 minutes in order to
allow for the diﬀusion of the injected volume and prevents
pressure-induced damage.
2.2. Drugs and Treatment. Colchicine (Sigma chemicals Co.,
St. Louis, USA) and standardized aqueous extract of Centella
asiatica (CA) (Dabur Research Foundation, Ghaziabad,
India) were used. Colchicine was prepared in ACSF such that
a1 5μg dose was delivered in a 5 μL injection volume for ICV
administration. For oral administration, aqueous extract of
CA was administered in a dose of 0.5mL/100g body weight.
Animals were divided randomly based on their body weights
into seven groups of 7 animals each. The groups were set as
shown in Table 1.
The doses of CA aqueous extract were selected based on
the previous studies in the laboratory and those reported in
the literature.
2.3. Behavioral Assessment
2.3.1. Assessment of Cognitive Performance
Elevated Plus Maze Paradigm. T h ee l e v a t e dp l u sm a z ec o n -
sisted of two opposite black open arms (50 × 10cm), crossed
with two closed walls of the same dimensions with 40cm
high walls. The arms were connected with a central square
of dimensions 10 × 10cm. The entire maze was elevated to
a height of 50cm from the ﬂoor. Acquisition of memory was
tested on day 13 after colchicine administration. Animal was
placed individually at one end of the open arm facing away
from the central square. The time taken by the animal to
move from the open arm to the closed arm was recorded
as the initial transfer latency (ITL). Animal was allowed to
explore the maze for 20 seconds after recording the ITL and
then returned to the home cage. If the animal did not enter
the enclosed arm within 90 seconds, it was guided on the
back into one of the enclosed arm and the ITL was given
as 90 seconds. Retention of memory was assessed by placing
the rat in an open arm and the retention latency was noted
on day 14 and day 21 of ITL and was termed as the ﬁrst
retention transfer latency (1st RTL) and second retention
transfer latency (2nd RTL), respectively [21].
Spatial Navigation Task. The acquisition and retention of a
spatial navigation task was evaluated by using Morris water
maze [22]. Animals were trained to swim toward a visible
platform in a circular pool (180cm in diameter and 60cmInternational Journal of Alzheimer’s Disease 3
in height) located in a test room. In principle, rats can escape
fromswimmingbyclimbingontotheplatformandovertime
the rats apparently learn the spatial location of the platform
from any starting position at the circumference of the pool.
Thus the platform oﬀers no local cues to guide the escape
behavior of the rats. The only spatial cues are those outside
of the tank primarily the visual cues. The pool was ﬁlled with
water (28 ± 2◦C )t oah e i g h to f4 0c m ,am o v a b l ec i r c u l a r
platform (9cm diameter), mounted on a column, was placed
in a pool 2cm above the water level during the acquisition
phase. A similar platform was placed in the pool 2cm below
the water level for the maze retention phase. The water was
made opaque by adding a nontoxic dye. Four equally spaced
locations around the edge of the pool (N, S, E, and W) were
used as starting points and this divided the pool into four
equal quadrants.
(1) Maze acquisition phase (training). Animals received
a training session consisting of 4 trials on day 13. In all 4
trials, the starting position was diﬀerent. A trial began by
releasing the animal into the maze facing towards the wall
of the pool. The latency to ﬁnd the escape platform was
recorded to a maximum of 90 seconds. If the rat did not
escape onto the platform within this time, it was guided to
the platform and was allowed to remain there for 20 seconds.
The time taken by rat to reach the platform was taken as the
initial acquisition latency (IAL).
(2) Maze retention phase (testing for retention of the
learned task). Following 24 hour (day 14) and 8 days (day
21) after IAL, the rat was released randomly from one of
the edges facing the wall of the pool. The time taken to
ﬁnd the hidden platform was recorded and termed as ﬁrst
retention latency (1st RL) and second retention latency (2nd
RL)onday14andday21followingcentraladministration of
colchicines, respectively.
2.3.2. Assessment of Gross Behavioral Activity. Gross behav-
ioral activity was observed on days 1, 7, 14, and 21 following
ICV colchicine injection. Animal was placed in a square
(30cm) closed arena equipped with infrared light-sensitive
photocells using digital photoactometer. The animals were
observed for a period of 5 minutes and the values were
expressed as counts/5 minutes [23].
2.4. Dissection and Homogenization. On day 24, after behav-
ioral assessments, animals were scariﬁed by decapitation
prior to deep anesthesia. The brains were removed, forebrain
was dissected out, and cerebellum was discarded. Brain was
put on ice and rinsed with ice-cold isotonic saline. A (10%
w/v) homogenate was prepared in 0.1M phosphate buﬀer
(pH 7.4). The homogenate was centrifuged at 10,000 g for
15 minutes and aliquots of supernatant was separated and
used for biochemical estimation.
2.5. Biochemical Tests
2.5.1. Measurement of Lipid Peroxidation. The extent of lipid
peroxidation in the brain was determined as described by
Wills [24]. The amount of malondialdehyde (MDA) was
measured by reaction with thiobarbituric acid at 532nm
using Perkin Elmer Lambda 20 spectrophotometer. The
values were calculated using the molar extinction coeﬃcient
of chromophore (1.56 × 105(mol/L)−1cm−1).
2.5.2. Estimation of Reduced Glutathione. Reduced glu-
tathione was estimated according to Ellman [25]. A 1-mL
supernatantwasprecipitatedwith1mLof4%sulphosalicylic
acid and cold digested for 1 hour at 4◦C. The samples
were then centrifuged at 1,200g for 15 minutes at 4◦C.
To 1mL of the supernatant obtained, 2.7mL of phosphate
buﬀer (0.1mmol/L, pH8 )a n d0 . 2 m Lo f5 ,5
  dithio-bis
(2-nitrobenzoic acid) (DTNB) was added. The developed
yellow color was measured at 412nm using Perkin Elmer
Lambda 20 spectrophotometer. Results were calculated using
themolarextinctionco-eﬃcientofthechromophore(1.36 ×
104 (mol/L)−1cm−1).
2.5.3. Estimation of Nitrite. The accumulation of nitrite in
the supernatant, an indicator of the production of nitric
oxide, was determined by a colorimetric assay with Greiss
reagent according to Green et al. [26]. The absorbance
was measured at 540nm using Perkin Elmer Lambda 20
spectrophotometer. The concentration of nitrite in the
supernatant was determined from sodium nitrite standard
curve.
2.5.4. Superoxide Dismutase Activity. Superoxide dismutase
(SOD) activity was assayed by the method of Kono [27].
The assay system consisted of EDTA 0.1mM, sodium
carbonate 50mM and 96mM of nitro blue tetrazolium
(NBT). In the cuvette, 2mL of the above mixture, 0.05mL of
hydroxylamine, and 0.05mL of the supernatant were added,
andtheauto-oxidationofhydroxylaminewasmeasuredfor2
minutes at 30-second interval by measuring the absorbance
at 560nm using Perkin Elmer Lambda 20 spectrophotome-
ter.
2.5.5. Catalase Activity. Catalase activity was assessed by the
method of Luck [28], wherein the breakdown of hydrogen
peroxide is measured. Brieﬂy, the assay mixture consisted of
3mLofH 2O2 phosphate buﬀer and 0.05mL of the super-
natant of the tissue homogenate. The change in absorbance
was recorded for 2 minutes at 30-second interval at 240nm
using Perkin Elmer Lambda 20 spectrophotometer. The
results were expressed as micromoles of H2O2 decomposed
per minute per mg protein.
2.5.6. Glutathione-S-Transferase Activity. The activity of
glutathione-S-transferase was assayed by the method of
Habig and Jakoby [29]. Brieﬂy, the assay mixture con-
sisted of 2.7mL of phosphate buﬀer, 0.1mL of reduced
glutathione,0.1mLof1-chloro-2,4-dinitrobenzene(CDNB)
as substrate, and 0.1mL of supernatant. The increase in
the absorbance was recorded at 340nm for 5 minutes at 1-
minute interval using Perkin Elmer Lambda 20 spectropho-
tometer. The results were expressed as nmoles of CDNB
conjugated/min/mg protein.4 International Journal of Alzheimer’s Disease
Table 2: Eﬀect of Centella asiatica (CA; 150 and 300mg/kg,
PO) on memory performance in elevated plus maze paradigm in
intracerebroventricular colchicines- (COL-) injected rats.
Treatment (mg/kg) Mean transfer latency (in seconds)
ITL 1st RTL 2nd RTL
Sham 58.16 ±1.79 20.5 ±4.28 17.0 ±5.16
ACSF 61.16 ±1.61 5 .66 ±1.66 12.60 ±1.49
COL 66.66 ±1.53a 79.33 ±1.33a 72.33 ±1.20a
CA (150) 62.16 ±1.51 19.16 ± 0.945 13.16 ±1.16
CA (300) 61.8 ±1.077 17.16 ±1.79 10.16 ±0.844
CA (150) + COL 66.3 ±1.470 49.33 ±0.881b 42.8 ±0.478b
CA (300) + COL 62.8 ± 1.238c 33.6 ±0.577b,c 29.44 ±0.958b,c
The initial transfer latencies (ITLs) on day 13 and retention transfer
latencies on days 14 (1st RTL) and 21 (2nd RTL) following colchicine
injection were observed. Values are mean ± SEM; aP<. 05 as compared to
artiﬁcialcerebrospinalﬂuid(ACSF)-injectedgroup; bP<. 05ascomparedto
colchicine-injected group; cP<. 05 as compared to CA (150) + COL group;
(repeated measures two-way ANOVA followed by Tukey’s test for multiple
comparisons).
Note: ACSF: artiﬁcial cerebrospinal ﬂuid; COL: colchicine; CA: Centella.
asiatica
2.5.7. Acetyl Cholinesterase (AChE) Activity. Acetyl cholin-
esterase (AChE) is a marker of extensive loss of cholinergic
neurons in the forebrain. The AChE activity was assessed
by Ellman method [30]. The change in absorbance was
measured for 2 minutes at 30-second interval at 412nm
using Perkin Elmer Lambda 20 spectrophotometer. Results
were expressed as micromoles of acetylthiocholine iodide
hydrolyzed per minute per mg protein.
2.5.8. Protein Estimation. The protein content was estimated
by biuret method [31] using bovine serum albumin as a
standard.
2.6.StatisticalAnalysis. Valuesareexpressedasmean ±SEM.
The behavioral assessment data were analyzed by a repeated
measures two-way ANOVA with drug-treated groups as
between and sessions as the within-subjects factors. The
biochemical estimations were separately analyzed by one-
way ANOVA. Post-hoc comparisons between groups were
made using Tukey’s test. The value P<. 05 was considered
signiﬁcant.
3. Results
3.1. Centella asiatica (CA) Improved on
Behavioral Alteration in Colchicine Treated Rats
3.1.1. Elevated Plus Maze. In the present experiment, mean
ITL on day 13 for each rat was relatively stable and showed
no signiﬁcant variation among diﬀerent groups. All the
rats entered the closed arm within 90 seconds. Following
training, sham-operated, ACSF-injected, and CA-treated
(150 and 300mg/kg, PO) rats entered closed arm quickly
as compared to colchicine treated rats. Mean retention
transfer latencies (1st RTL and 2nd RTL) to enter closed
Table 3: Eﬀect of Centella asiatica (CA; 150 and 300mg/kg, PO)
on spatial navigation task in intracerebroventricular colchicines-
(COL-) injected rats.
Treatment (mg/kg) Mean latency (in seconds)
IAL 1st RL 2nd RL
Sham 43.5 ±1.29 12.33 ±1.49 .16 ±2.16
ACSF 55.33 ±1.71 4 .33 ±1.66 11.8 ±1.49
COL 88.0 ±1.93a 75.0 ±1.43a 62.33 ±1.80a
CA (150) 62.33 ±1.51 12.83 ±1.945 10.16 ±2.16
CA (300) 60.8 ±1.077 11.83 ±1.09 9.66 ± 1.421
CA (150) + COL 70.6 ±2.470b 40.0 ±1.577b 32.15 ±0.475b
CA (300) + COL 66.66 ±1.438b,c 26.0 ±0.569b,c 21.5 ±1.576b,c
The initial acquisition latencies (IALs) on day 13 and retention latencies
on days 14 (1st RL) and 21 (2nd RL) following colchicine injection were
observed in Morris water maze. Values are mean ± SEM; aP<. 05 as
compared to artiﬁcial cerebrospinal ﬂuid- (ACSF) injected group; bP<. 05
ascomparedtocolchicine-injectedgroup; cP<. 05ascomparedtoCA(150)
+COLgroup;(Repeatedmeasurestwo-wayANOVAfollowedbyTukey’stest
for multiple comparisons).
Note: ACSF: artiﬁcial cerebrospinal ﬂuid; COL: colchicine; CA: Centella
asiatica.
arm on days 14 and 21 were shorter as compared to ITL on
day 13 of each group, respectively. In contrast, colchicine-
injected rats performed poorly throughout the experiment
and did not show any change in the mean retention transfer
latencies on days 14 and 21 as compared to pretraining
latency on day 13, demonstrating that colchicines-induced
marked memory impairment. Chronic administration of CA
(150 and 300mg/kg) beginning prior to colchicine injection
signiﬁcantly decreased the mean retention latencies on days
14 and 21 following colchicine injection (P<. 05 versus ICV
colchicine group) (Table 2). The mean transfer latencies of
CA- treated (150 and 300mg/kg, PO) and ICV colchicines-
treated groups were signiﬁcantly diﬀe r e n tf r o mt h a to fC A
p e rs eg r o u p so nd a y s1 4a n d2 1( P<. 05) (Table 2)
3.1.2. Morris Water Maze. Sham-operated, ACSF-injected,
and CAper se (150 and 300mg/kg, PO) group of animals
quickly learned to swim directly to the platform in the
Morris water maze on day 13. Colchicine-treated rats
showed an initial increase in escape latency, which declined
with continued training during the acquisition of a spatial
navigation task on day 13. CA (150 and 300mg/kg, PO)
group of rats was also performed similarly during the
acquisition of a spatial navigation task on day 13 (versus
ACSF-injected group). There was a signiﬁcant diﬀerence
in the mean IAL of colchicines-treated group compared
to ACSF-injected group on day 13 indicating colchicine-
induced impaired acquisition of spatial navigation task (P<
.05). In contrast, CA (150 and 300mg/kg, PO) treatment
signiﬁcantly decreased the IAL to reach the platform in the
pretrained rats as compared to colchicine treated rats on day
13 following colchicine administration (Table 3).
Following training, the mean retention latencies (1st
and 2nd RL) to escape onto the hidden platform were
signiﬁcantly decreased in sham-operated and ACSF-injected
rats on days 14 and 21, respectively, as compared to IAL onInternational Journal of Alzheimer’s Disease 5
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Figure 1: Centella asiatica (CA; 150 and 300mg/kg, PO) on
locomotor activity in intracerebroventricular colchicines- (COL-)
injected rats. Values are mean ± SEM. Data was analyzed by two-
way anova (n = 12 in each group).
day 13 following colchicine administration. On the contrary,
the performance in the colchicines-treated rats was changed
afterinitialtraininginthewatermazeondays14and21,with
signiﬁcant increase in mean retention latencies compared
to IAL on day 13. The results suggest that colchicine
caused signiﬁcant cognitive impairment. However, chronic
CA treatment (150 and 300mg/kg, PO) starting before
colchicine administration showed a signiﬁcant decline in the
1st and 2nd RL as compared to colchicines-treated rats on
days 14 and 21, respectively, following colchicine adminis-
tration (Table 3) and improved the retention performance of
the spatial navigation task.
3.2. Eﬀect of Centella Asiatica on Locomotor Activity. In the
present series of experiments, the mean scores of locomotor
activity for each rat were relatively stable and showed no
signiﬁcant variation among diﬀerent groups. The mean
scores in sham-operated, ACSF-, and colchicines-treated rats
remained unchanged. Further, both the dose of CA (150 and
300mg/kg,PO)didnotcauseanysigniﬁcantalterationinthe
locomotor activity as compared to colchicine treated rats on
days 14 and 21 (Figure 1).
3.3. Antioxidant Eﬀect of Centella Asiatica (CA) in Colchicine-
Treated Rats. Central administration of colchicine caused
signiﬁcant rise in brain MDA, nitrite levels, depletion
of GSH, glutathione-S-transferase, SOD, and catalase lev-
els as compared to ACSF. However, chronic CA (150
and 300mg/kg, PO) treatment signiﬁcantly attenuated the
increase in MDA, nitrite levels, and restored decrease in
reduced GSH (Table 3). CA treatment also caused a signiﬁ-
cant increase in glutathione-S-transferase, SOD, and catalase
levels (Table 4).
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Figure 2: Centella asiatica (CA; 150 and 300mg/kg, PO) on
acetyl cholinesterase activity in Intracerebroventricular colchicines-
(COL-) treated rats. Values are mean ± SEM; aP<. 05 as compared
to artiﬁcial cerebrospinal ﬂuid- (aCSF-) injected group; bP<. 05
as compared to colchicine treated group; cP<. 05 as compared to
CA (150) + COL group; (one-way ANOVA followed by Turkey’s
test for multiple comparisons). Note: aCSF: artiﬁcial cerebrospinal
ﬂuid; COL: colchicine; CA: Centella asiatica
3.4.ReversalofIncreasedBrainAcetylcholineLevelsbyCentella
Asiatica in Colchicine-Treated Rats. Intracerebroventricular
administration of ACSF did not show any signiﬁcant
eﬀect on brain acetylcholinesterase levels as compared to
sham-operated rats. In contrast, central colchicine injection
showed signiﬁcant increase in the brain AChE activity as
compared to ACSF-injected rats. However, chronic oral
administration of CA (150mg/kg and 300mg/kg, PO)
signiﬁcantlyattenuatedenhancedAChEactivitycomparedto
colchicines-treated group (Figure 2).
4. Discussion
The present study investigated the eﬀect of Centella asiatica
(CA) extract in the prevention of sporadic dementia of
Alzheimer’s type using intracerebroventricular colchicines-
induced rats. Salient ﬁndings of this study are that pre-
and postcolchicine treatment with CA improved cogni-
tion, decreased malondialdehyde, and nitrite levels, restored
decrease in GSH, increased activities of glutathione-S-
transferase, catalase, and SOD. This illustrates that central
administration of colchicine is characterized by progressive
deterioration of learning and memory, oxidative stress, and
decrease in acetylcholine turnover [32, 33]. Cytoskeletal
disruption has been linked to neurodegeneration in AD [34].
Colchicine is an alkaloid derivative that binds irreversibly
to microtubules and causes their depolymerization, thereby
inhibiting their assembly. This leads to impaired intracel-
lular traﬃcking of neurotrophic factors, synaptic loss, and
increased axonal excitotoxicity [35].
In the present study, colchicine when given centrally
resulted in signiﬁcant memory impairment in elevated plus
maze and Morris water maze tasks which were attenuated
by chronic CA treatment. In the present study, chronic6 International Journal of Alzheimer’s Disease
Table 4: Eﬀect of Centella asiatica (CA; 150 and 300 mg/kg, PO) on colchicines-induced oxidative stress parameters in rat brain.
Treatment (mg/kg)
MDA levels
nmol MDA/mg
protein (% of
sham)
Nitrite levels
μmol/mg
protein (% of
sham)
Reduced
glutathione
nmol/mg
protein (% of
sham)
Catalase μmol
of hydrogen
peroxide
decom-
posed/min/mg
protein ( % of
sham)
Superoxide
dismutase
Units/mg
protein (% of
sham)
Glutathione- S-
transferase
nmol of CDNB
conju-
gated/min/mg
protein (% of
sham)
Sham 100 ± 10 100 ± 12 100 ± 10 100 ± 12 100 ± 14 100 ± 12
ACSF 114.28 ± 11 109.33 ± 11 103.33 ± 11 97.05 ± 10 97.52 ± 15 98.66 ± 16
COL 339.88 ± 32a 298.39 ± 15a 23.38 ± 10a 17.98 ±8a 13.47 ±3a 18.67 ±7a
CA (150) 106.7 ± 15 101.29 ± 16 90.35 ± 17 93.9 ± 13.7 99.17 ± 17 97.64 ± 14
CA (300) 123.4 ± 28 99.44 ± 26 93.77 ± 15 98.8 ± 10.8 98.16 ± 16 98.65 ± 13
CA (150) + COL 229.81 ± 27b 210.91 ±8b 50.45 ±8b 36.96 ±6b 39.05 ± 10b 30.65 ±8b
CA (300) + COL 157.26 ± 16b,c 148.98 ± 7.9b,c 81.61 ± 7.6b,c 69.71 ±5b,c 65.52 ±5b,c 65.05 ±6b,c
Values are mean ± SEM; aP<. 05 as compared to artiﬁcial cerebrospinal ﬂuid- (ACSF-) injected group; bP<. 05 as compared to colchicine-injected group;
cP<. 05 as compared to CA (150) + COL group; (repeated measures two-way ANOVA followed by Tukey’s test for multiple comparisons).
Note: ACSF: artiﬁcial cerebrospinal ﬂuid; COL: colchicine; CA: Centella asiatica.
administration of CA was able to improve the cognitive
deﬁcit and attenuated oxidative stress, suggesting that CA
improves cognitive task and has antioxidant-like eﬀect [16,
36]. Additionally, CA leaf extract has been reported to
improve spatial learning performance and enhance memory
retention in neonatal rats during growth spurt period
a n da l s of o u n de ﬃcient in enhancing hippocampal CA3
neuronaldendritic arborization in rats [18, 37].
Lipid peroxidation plays a major role in oxidative
damage of lipids. The key metabolites of lipid oxidation are
malondialdehyde (MDA) and 4-hydroxynonenal (HNE). It
has been reported that the level of MDA are generally higher
in AD. Further, it has been supported that the level of HNE
also found abundantly in on apolipoprotein E in vitro and
on cyto skeletal proteins in cell culture [38]. Our results also
proved that the administration of colchicine produced the
increased MDA levels which are more responsible for the
oxidative damage in rats.
A growing body of evidence supports the fact that free
radicals are the most likely candidates responsible for pro-
ducing neuronal changes mediating the behavioral deﬁcits in
AD [39, 40]. In fact, there exists a close correlation between
oxidative stress and Aβ deposition [41]. Although colchicine
is one of themajor oxidative medication of proteins resulting
from peroxynitrite which is associated with free radical
and nitric oxide, central administration of colchicine causes
oxidative stress by increasing GLU/GABA ratio [42]a n d
increasing NOS production in the brain [43] . This results
in an excessive glutamate activity [44]a n dN Op r o d u c t i o n
thereby resulting in oxidative stress and extensive neuronal
damage [45]. NOS-containing neurons are relatively wide
spread in AD. It has been reported that activated microglia
are widely abundant in most senile plaque in AD which
are responsible for the production of nitric oxide [46].S o
it seems that the production of nitric oxide produced by
oxidative stress with colchicine is an additional link to lower
incidence of AD with use of antioxidant agent.
In the present study, CA per se did not show any
signiﬁcant eﬀect on the oxidative stress markers in the brain
of normal animals. However, CA treatment signiﬁcantly
attenuated the colchicines-induced oxidative stress. The
main chemical constituents of CA are triterpenes mainly
pentacyclic triterpenic acids and their respective glyco-
sides, including asiatic acid, asiaticoside, madecassic acid,
madecassoside, brahmoside, brahmic acid, brahminoside,
thankuniside, isothankuniside, centelloside, madasiatic acid,
centic acid, and cenellicacid [47]. Beside triterpenoids and
essentialoils,CAhasalsobeenreportedtocontainnumerous
ﬂavonoids, including quercetin, kaempferol, catechin, rutin,
and naringin, some of which are major contributors in
particular to the antioxidative activity of CA [48]. CA has
been recently indicated to show antilipid peroxidative and
free radical scavenging activities [49, 50].
Glutathione is an endogenous antioxidant presenting
in the reduced form within the cells. It has been shown
to react with free radicals and prevent generation of
hydroxyl free radicals [51]. The decreased level of GSH
and glutathione-S-transferase activity in colchicines-treated
animals indicates that there is an increased generation of
free radicals and reduced activity of glutathione system in
combating oxidative stress. CA treatment was able to restore
the GSH levels and also cause a signiﬁcant increase in the
glutathione-S-transferase activity. Central administration of
colchicine causes an increase in expression of NOS resulting
in increased levels of NO which is neurotoxic to cholinergic
neurons [52]. Nitric oxide also acts as a precursor for perox-
ynitrite free radical which results in neuronal damage. This
explains that central administration of colchicine caused a
signiﬁcant increase in the nitrite levels in the brain and
CA treatment was able to decrease the raised nitrite levels.
Colchicine also induces a direct inﬂammatory response in
the CNS [53] which causes cholinotoxicity. Jin et al. [54]
showed that CA aqueous extract which contains asiaticoside
has an anti-inﬂammatory property that is brought about byInternational Journal of Alzheimer’s Disease 7
inhibition of NO synthesis. This may also have a role in
explaining the neuroprotective eﬀect of CA.
Central administration of colchicine produces marked
destruction of hippocampal granule cells and septohip-
pocampal pathways resulting in loss of cholinergic neurons
and decreased activities of acetylcholinesterase and choline
acetyltransferase [8]. In the present study, colchicine caused
a signiﬁcant increase in the acetylcholinesterase activity
thereby leading to learning and memory deﬁcits. CA was
able to ameliorate the colchicine induced decrease in AChE
activity. In summary, the present study suggests that chronic
administration of CA prevents colchicine-induced cognitive
impairment and associated oxidative stress. Thus, the use
of CA is promising for the treatment of AD and other
neurodegenerative disorders.
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